Search all trials

Find therapies in clinical trials near you – page 29

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Breast cancer

Not yet recruiting

Registered drugNo placebo

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

Pneumonia

Not yet recruiting

Registered drugNo placebo

Study of Baricitinib for Treating Hospital-Acquired Pneumonia in Critically Ill Patients with a Proinflammatory Profile

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Baricitinib

Contact Research Centre

Acute lymphocytic leukaemia

Not yet recruiting

Registered drugNo placebo

Study on Pegaspargase for Treating Acute Lymphoblastic Leukemia in Children and Adolescents

Registered drugNo placebo

France

Participants:0–17 years
Substances:Pegaspargase

Contact Research Centre

Anti-myelin-associated glycoprotein associated polyneuropathy

Not yet recruiting

Registered drug

Study of Rituximab compared to placebo in patients with anti-MAG neuropathy who are likely to respond well to treatment

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Rituximab

Contact Research Centre

Sjogren's syndrome

Not recruiting

Investigational

Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational

France

Participants:18–64 years · 65+ years
Substances:Dazodalibep

Contact Research Centre

Sjogren's syndrome

Not recruiting

Investigational

Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational

France

Participants:18–64 years · 65+ years
Substances:Dazodalibep

Contact Research Centre

Chronic kidney disease+1

Not recruiting

Investigational

A Study Testing How Well BAY 3401016 Works and How Safe It Is in Adults Aged 18 to 45 Years with Alport Syndrome

Investigational

France

Participants:18–64 years

Contact Research Centre

Dermatitis atopic

Not recruiting

Investigational

Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Investigational

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Rocatinlimab

Contact Research Centre

Dermatitis atopic

Not recruiting

Registered drug

Study of rocatinlimab (AMG 451) in adolescents with moderate to severe atopic dermatitis to evaluate its effectiveness and safety over 52 weeks

Registered drug

France

Participants:0–17 years

Contact Research Centre

Hidradenitis

Not recruiting

InvestigationalNo placebo

Long-term safety and effectiveness study of sonelokimab injections for patients with moderate to severe hidradenitis suppurativa

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Sonelokimab

Contact Research Centre

Sjogren's syndrome

Not recruiting

Investigational

Study on the Effectiveness and Safety of Nipocalimab for Adults with Moderate to Severe Sjögren's Disease

Investigational

France

Participants:18–64 years · 65+ years
Substances:Nipocalimab

Contact Research Centre

Muscle spasticity

Not recruiting

Registered drug

Study on the Safety and Effectiveness of IPN10200 for Treating Upper Limb Spasticity in Adults After Stroke or Brain Injury

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Botulinum Toxin Type A - Haemagglutinin Complex

Contact Research Centre

Find therapies in clinical trials near you – page 29

584 trials match your criteria

Breast cancer

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Pneumonia

Study of Baricitinib for Treating Hospital-Acquired Pneumonia in Critically Ill Patients with a Proinflammatory Profile

Acute lymphocytic leukaemia

Study on Pegaspargase for Treating Acute Lymphoblastic Leukemia in Children and Adolescents

Anti-myelin-associated glycoprotein associated polyneuropathy

Study of Rituximab compared to placebo in patients with anti-MAG neuropathy who are likely to respond well to treatment

Sjogren's syndrome

Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Sjogren's syndrome

Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Chronic kidney disease+1

A Study Testing How Well BAY 3401016 Works and How Safe It Is in Adults Aged 18 to 45 Years with Alport Syndrome

Dermatitis atopic

Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Dermatitis atopic

Study of rocatinlimab (AMG 451) in adolescents with moderate to severe atopic dermatitis to evaluate its effectiveness and safety over 52 weeks

Hidradenitis

Long-term safety and effectiveness study of sonelokimab injections for patients with moderate to severe hidradenitis suppurativa

Sjogren's syndrome

Study on the Effectiveness and Safety of Nipocalimab for Adults with Moderate to Severe Sjögren's Disease

Muscle spasticity

Study on the Safety and Effectiveness of IPN10200 for Treating Upper Limb Spasticity in Adults After Stroke or Brain Injury

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.